← All trials
NCT05768321
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2021
- Primary completion
- Feb 28, 2024
- Completion date
- May 30, 2024
- First posted
- Mar 14, 2023
- Last posted
- Mar 16, 2023
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GenEros Biopharma Hangzhou LtdLead sponsor
- Sichuan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.